TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

BRUKINSA® Granted Approval in Canada for Treating Chronic Lymphocytic Leukemia

Tuesday, May 30, 2023

BeiGene, Ltd., a global biotechnology company, announced that Health Canada has approved BRUKINSA (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in adult patients. This marks an important milestone for BRUKINSA, as it becomes available as a treatment option for CLL patients in Canada. CLL is a common form of leukemia, primarily affecting individuals over the age of 60.

BRUKINSA is a Bruton's tyrosine kinase inhibitor (BTKi) and has shown promising efficacy and a favorable safety profile in clinical trials. It has been evaluated in two Phase 3 trials: SEQUOIA, which compared BRUKINSA to bendamustine plus rituximab in previously untreated CLL patients, and ALPINE, which compared BRUKINSA to ibrutinib in relapsed or refractory CLL patients. The results demonstrated superior efficacy of BRUKINSA over the comparator treatments.

The approval of BRUKINSA by Health Canada provides CLL patients in Canada with an additional treatment option, highlighting the ongoing commitment to address the needs of patients with this condition. BRUKINSA has already received approvals in various countries around the world, making it a globally recognized treatment option for CLL.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit